FASLG and autoimmune polyendocrinopathy: The European Medicines Agency (123), following a risk assessment triggered by Rivaroxaban for thrombotic APS randomized controlled trials, has stated that DOACs are not recommended for patients with thrombotic APS, especially those with triple aPL positivity.